Phase 1 trial results from a novel long acting NPY2-receptor agonist in partnership between Gubra A/S and Boehringer Ingelheim presented today at the European Congress on Obesity, ECO 2023

- BI 1820237 a novel long-acting neuropeptide Y receptor type 2 (NPY2) agonist, has been evaluated in a phase 1 clinical trial.
- Results to be presented today at the ECO 2023 congress in Dublin, Ireland.
- The trial showed no unexpected safety concerns, and positive effects on energy intake and gastric emptying.
- BI 1820237 originates from an ongoing collaboration between Boehringer Ingelheim and Gubra A/S.

Today, at the 30th European Congress on Obesity (ECO 2023) in Dublin, Ireland, Boehringer Ingelheim shares phase 1 results for BI 1820237, a long acting NPY2 receptor agonist drug candidate developed in collaboration with Gubra A/S.

The phase 1 trial (NCT04903509) was a placebo-controlled study consisting of 3 parts: Part 1: testing single increasing subcutaneous doses of the novel NPY2 receptor agonist, part 2: increasing the number of participants in the high dose group and part 3: exploring low-to-medium doses of the NPY2 receptor agonist in combination with low-dose liraglutide. Participants in the trial were healthy men with overweight/obesity. The results show no unexpected safety or tolerability concerns with single doses of BI 1820237 with and without liraglutide. Adverse events were primarily gastro-intestinal in nature and the frequency increased with increasing dose. Treatment with BI 1820237 decreased energy intake and delayed gastric emptying in healthy men with overweight/obesity, supporting further investigations of the drug candidate.

Niels Vrang, Chief Scientific Officer at Gubra A/S, expressed satisfaction with the results and the continued development of this peptide by Boehringer Ingelheim as a potential anti-obesity medication:

"We are excited to see data from the phase 1 trial presented by Boehringer Ingelheim at the annual European Congress on Obesity. Data are in line with observations in several animal models. We look forward to seeing how this NPY2-receptor agonist can be used in combination with

approved obesity drugs, e.g. GLP-1 receptor agonists and other obesity drug candidates currently in development, to potentially improve therapy - better effect and/or a better tolerability profile for the benefit for people living with obesity. It will be exciting to follow this project as it moves forward."

Contacts at Gubra

Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586
Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Gubra

Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

Attachments

Phase 1 trial results from a novel long acting NPY2-receptor agonist in partnership between Gubra A/S and Boehringer Ingelheim presented today at the European Congress on Obesity, ECO 2023